You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Primary Cutaneous Anaplastic Large-cell Lymphoma

Perry, Edward MD; Karajgikar, Jay BA; Tabbara, Imad A. MD

American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e3182185aa2
Review Articles
Abstract

Since the recognition of the anaplastic large-cell lymphomas in the 1980s, much has been learned about the diagnosis, clinical presentation, and treatment of these malignant conditions. The systemic and primary cutaneous types of anaplastic large cell lymphomas have been differentiated on clinical and immunophenotypical findings, but further research is required to elucidate their exact etiologies and pathogeneses. Primary cutaneous anaplastic large-cell lymphoma has a 95% disease-specific 5-year survival, owing partly to the relatively benign course of the disease and partly to the variety of effective treatments that are available. As with many other oncological diseases, new drugs are continually being tested and developed, with immunotherapy and biological response modifiers showing promise.

Author Information

Division of Hematology and Oncology, Department of Medicine, George Washington University School of Medicine, Washington, DC

Reprints: Imad A. Tabbara, MD, Bone Marrow Transplant Program, 2150 Pennsylvania Avenue, NW, Washington, DC 20037. e-mail: itabbara@mfa.gwu.edu.

The authors declare no conflicts of interest.

© 2013 by Lippincott Williams & Wilkins, Inc